{'fraction_non_alphanumeric': 0.031938325991189426, 'fraction_numerical': 0.005506607929515419, 'mean_word_length': 5.7835820895522385, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A multicenter clinical trial of recombinant human GM‐CSF hydrogel for the treatment of deep second‐degree burns

Wound healing is a complex and dynamic biological process. The efficacy and safety of a recombinant human granulocyte‐macrophage colony‐stimulating factor (rhGM‐CSF) hydrogel to promote deep‐second‐degree burn wound healing is evaluated in this study. In this multicenter, randomized, double‐blind, and placebo‐controlled clinical trial, 90 patients with deep second‐degree burns were randomly assigned into two groups. Complete healing time and percentage of wound healing at different time points were observed and side effects were recorded. A statistically significant difference was noted at each time point (p<0.01). No side effects were observed. These results suggest that rhGM‐CSF hydrogel can significantly accelerate deep second‐degree burn wound healing and is considered to be safe.